ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BMS Links With Japanese Firms

by Michael McCoy
March 9, 2009 | APPEARED IN VOLUME 87, ISSUE 10

Bristol-Myers Squibb is collaborating with the Japanese companies Nissan Chemical Industries and Teijin Pharma to develop Nissan’s NTC-801 outside Japan. Teijin already has Japanese rights. A selective inhibitor of the acetylcholine-activated potassium ion channel, NTC-801 is currently in Phase I development in Japan for treating a form of arrhythmia. BMS will pay $40 million up front and potentially make milestone payments of up to $170 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment